Empagliflozin and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Empagliflozin (empagliflozin), especially for people who are male, 60+ old, have been taking the drug for 2 - 5 years also take Metformin, and have Cardiac failure.

The study is created by eHealthMe based on reports of 1,555 people who have side effects when taking Empagliflozin from the FDA, and is updated regularly.

What is Empagliflozin?

Empagliflozin has active ingredients of empagliflozin. eHealthMe is studying from 1,569 Empagliflozin users. Check the latest studies of Empagliflozin.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 10, 2026

1,555 people reported to have side effects when taking Empagliflozin.
Among them, 12 people (0.77%) died.

Among these 12 people:

How long have people been on Empagliflozin when they died? *

What is the gender of people who died when taking Empagliflozin? *

female: 0.0 %
male: 100 %

What is the age of people who died when taking Empagliflozin? *

What are other drugs people take besides Empagliflozin? *

What are other side effects people have before they died? *

Hypotension (abnormally low blood pressure): 2 people, 16.67%
Renal Impairment (severely reduced kidney function): 1 person, 8.33%
Pyoderma Gangrenosum (ulcerating condition of skin that results in heaped borders with a typical appearance): 1 person, 8.33%
Nausea And Vomiting: 1 person, 8.33%
Medical Device Discomfort (difficulty due to medical devices): 1 person, 8.33%
Limb Injury: 1 person, 8.33%
Insomnia (sleeplessness): 1 person, 8.33%
Infarction (obstruction of the blood supply to an organ or region of tissue): 1 person, 8.33%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 8.33%
Fall: 1 person, 8.33%

What are the existing conditions these people have? *

Cardiac Failure: 3 people, 25.00%
Type 2 Diabetes: 2 people, 16.67%
Diabetes: 2 people, 16.67%
Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 1 person, 8.33%
High Blood Cholesterol: 1 person, 8.33%
Completed Suicide (act of taking one's own life): 1 person, 8.33%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 8.33%
Amyloidosis (a tumour within which amyloid is produced): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Empagliflozin:

Empagliflozin (1,569 reports)

Expand to all the drugs that have ingredients of empagliflozin:

Death and drugs with ingredients of empagliflozin (624 reports)

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Empagliflozin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,107 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on empagliflozin (the active ingredients of Empagliflozin) and Empagliflozin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.